MIDLOTHIAN, Va., March 1 Today, PARI Respiratory Equipment launched their newest aerosol delivery system, the Vios. Paired with PARI's gold standard reusable nebulizers, Vios delivers fast treatments, ...
Respiratory devicemaker PARI picked up an approval from the FDA for its eRapid nebulizer system, which is the first electronic one to deliver Genentech's cystic fibrosis treatment Pulmozyme. A ...
STARNBERG, Germany, June 7, 2016 /PRNewswire/ -- PARI Pharma, a company focused on the development of advanced aerosol therapies using eFlow Technology, announces that its proprietary closed eFlow ...
As highlighted in the April issue of Medical Device & Diagnostic Industry magazine, PARI Aerosol Research Institute has been awarded a 2006 Medical Design Excellence Award for eFlow. eFlow is an ...
The US Food and Drug Administration (FDA) has approved the eRapid nebulizer system (PARI), the first electronic nebulizer to deliver dornase alfa (Pulmozyme, Genentech) for the treatment of cystic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback